Qiuhong Gong1, Ping Zhang2, Jinping Wang3, Edward W Gregg4, Yiling J Cheng2, Guangwei Li1,5, Peter H Bennett6. 1. Endocrinology and Cardiovascular Disease Center, National Center of Cardiology & Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 3. Department of Cardiology, Da Qing First Hospital, Da Qing, China. 4. Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. 5. China-Japan Friendship Hospital, Beijing, China. 6. Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, USA.
Abstract
AIMS: The extent that pre-diabetic fasting plasma glucose (FPG) levels influence the effectiveness of lifestyle interventions in preventing type 2 diabetes (T2DM) is uncertain. We aimed to determine if the outcome of lifestyle intervention in people with impaired glucose tolerance (IGT) differs in those with normal or impaired FPG levels. MATERIALS AND METHODS: Data were used from the Da Qing Diabetes Prevention Outcome Study, which was a 30-year follow-up of a 6-year randomized trial of lifestyle intervention in 576 people with IGT. We then conducted a post-hoc analysis to compare the efficacy of intervention to reduce the incidence of T2DM and its complications in those with baseline FPG <100 mg/dL and FPG ≥100 mg/dL. RESULTS: Lifestyle intervention reduced the cumulative incidence of T2DM by 37%-46% in those with baseline FPG <100 mg/dL and by 47%-51% in those with FPG ≥100 mg/dL. The FPG <100 mg/dL group had a lower cumulative incidence of diabetes and 6.41 years median delay in its onset compared with 2.21 years delay in the FPG ≥100 mg/dL group. In those with FPG <100 mg/dL intervention was associated with at least as great a reduction in cardiovascular disease and all-cause mortality as in the FPG ≥100 mg/dL group. CONCLUSIONS: Lifestyle intervention reduced the incidence of T2DM in people with IGT regardless of baseline FPG levels, and in those with FPG <100 mg/dL led to a substantial delay in its onset. All persons with IGT, with normal or impaired FPG levels, may benefit from lifestyle intervention to delay its onset and mitigate the incidence of T2DM.
AIMS: The extent that pre-diabetic fasting plasma glucose (FPG) levels influence the effectiveness of lifestyle interventions in preventing type 2 diabetes (T2DM) is uncertain. We aimed to determine if the outcome of lifestyle intervention in people with impaired glucose tolerance (IGT) differs in those with normal or impaired FPG levels. MATERIALS AND METHODS: Data were used from the Da Qing Diabetes Prevention Outcome Study, which was a 30-year follow-up of a 6-year randomized trial of lifestyle intervention in 576 people with IGT. We then conducted a post-hoc analysis to compare the efficacy of intervention to reduce the incidence of T2DM and its complications in those with baseline FPG <100 mg/dL and FPG ≥100 mg/dL. RESULTS: Lifestyle intervention reduced the cumulative incidence of T2DM by 37%-46% in those with baseline FPG <100 mg/dL and by 47%-51% in those with FPG ≥100 mg/dL. The FPG <100 mg/dL group had a lower cumulative incidence of diabetes and 6.41 years median delay in its onset compared with 2.21 years delay in the FPG ≥100 mg/dL group. In those with FPG <100 mg/dL intervention was associated with at least as great a reduction in cardiovascular disease and all-cause mortality as in the FPG ≥100 mg/dL group. CONCLUSIONS: Lifestyle intervention reduced the incidence of T2DM in people with IGT regardless of baseline FPG levels, and in those with FPG <100 mg/dL led to a substantial delay in its onset. All persons with IGT, with normal or impaired FPG levels, may benefit from lifestyle intervention to delay its onset and mitigate the incidence of T2DM.
Authors: David M Nathan; Mayer B Davidson; Ralph A DeFronzo; Robert J Heine; Robert R Henry; Richard Pratley; Bernard Zinman Journal: Diabetes Care Date: 2007-03 Impact factor: 19.112
Authors: Q Gong; E W Gregg; J Wang; Y An; P Zhang; W Yang; H Li; H Li; Y Jiang; Y Shuai; B Zhang; J Zhang; R B Gerzoff; G Roglic; Y Hu; G Li; P H Bennett Journal: Diabetologia Date: 2010-11-03 Impact factor: 10.122
Authors: Ethan Paddock; Maximilian G Hohenadel; Paolo Piaggi; Pavithra Vijayakumar; Robert L Hanson; William C Knowler; Jonathan Krakoff; Douglas C Chang Journal: Diabetologia Date: 2017-06-29 Impact factor: 10.122
Authors: Matthew D Campbell; Thirunavukkarasu Sathish; Paul Z Zimmet; Kavumpurathu R Thankappan; Brian Oldenburg; David R Owens; Jonathan E Shaw; Robyn J Tapp Journal: Nat Rev Endocrinol Date: 2020-02-14 Impact factor: 43.330
Authors: Jaana Lindström; Markku Peltonen; Johan G Eriksson; Sirkka Aunola; Helena Hämäläinen; Pirjo Ilanne-Parikka; Sirkka Keinänen-Kiukaanniemi; Matti Uusitupa; Jaakko Tuomilehto Journal: Diabetes Care Date: 2008-02-05 Impact factor: 19.112
Authors: Cherie James; Kai McKeever Bullard; Deborah B Rolka; Linda S Geiss; Desmond E Williams; Catherine C Cowie; Ann Albright; Edward W Gregg Journal: Diabetes Care Date: 2011-02 Impact factor: 19.112